Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Pidnarulex

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    US FDA Issues Study May Proceed Letter For Pidnarulex
    US FDA Issues Study May Proceed Letter For Pidnarulex

    14 Oct 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/us-fda-issues-study-may-proceed-letter-for-the-pilot-study-of-pidnarulex-pharmacodynamics-in-patients-with-advanced-solid-tumors-sponsored-by-the-us-national-cancer-institute-302274665.html

    PR NEWSWIRE
    14 Oct 2024
    Share Share
    Senhwa Submits IND For Pidnarulex Study In Advanced Solid Tumors To US FDA
    Senhwa Submits IND For Pidnarulex Study In Advanced Solid Tumors To US FDA

    17 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/senhwa-biosciences-announces-ind-submission-to-us-fda-for-pilot-study-of-pidnarulex-pharmacodynamics-in-patients-with-advanced-solid-tumors-sponsored-by-nci-302251175.html

    PR NEWSWIRE
    17 Sep 2024
    Share Share
    Senhwa Presents Pidnarulex Clinical Data At ESMO 2024
    Senhwa Presents Pidnarulex Clinical Data At ESMO 2024

    08 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/senhwa-biosciences-presents-clinical-data-abstract-on-pidnarulex-at-2024-esmo-congress-302241441.html

    PR NEWSWIRE
    08 Sep 2024
    Share Share
    Senhwa Announces Successful Awardee of Anticancer Pipeline in NExT Program
    Senhwa Announces Successful Awardee of Anticancer Pipeline in NExT Program

    01 Dec 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/senhwa-biosciences-announces-successful-awardee-of-anticancer-pipeline-pidnarulex-in-nih-sponsored-next-program-301691159.html

    PRNEWSWIRE
    01 Dec 2022
    Share Share
    Senhwa's Pidnarulex Receives US FDA FTD for Solid Tumors with BRCA1/2, PALB2
    Senhwa's Pidnarulex Receives US FDA FTD for Solid Tumors with BRCA1/2, PALB2

    25 Jan 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/senhwas-pidnarulex-receives-us-fda-fast-track-designation-for-the-treatment-of-solid-tumors-with-brca12-palb2-and-other-hr-gene-mutations-301467006.html

    PRNEWSWIRE
    25 Jan 2022
    Share Share
    Senhwa initiates dosing in PIb expansion study of Pidnarulex in solid tumors
    Senhwa initiates dosing in PIb expansion study of Pidnarulex in solid tumors

    13 Sep 2021

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=142471&sid=2

    PHARMABIZ
    13 Sep 2021
    Share Share